SamuelAaronGoldlustMD

Neurology • Kansas City, MO

Neurooncology

Medical Director, Neuro-Oncology

Join to view full profile

Dr. Goldlust is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Goldlust's full profile

Already have an account?

Office
4401 Wornall Road
Kansas City, MO 64111

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Neuro-Oncology, 2009 - 2011
NYU Grossman School of MedicineResidency, Neurology, 2006 - 2009
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 2005 - 2006
Ohio State University College of MedicineClass of 2005

Certifications & Licensure

MO State Medical License 2023 - 2026
KS State Medical License 2023 - 2025
NJ State Medical License 2011 - 2023
NY State Medical License 2008 - 2011
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01
Active, not recruiting
Phase 3
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Start of enrollment: 2011 Dec 01
Completed
Phase 2
The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment Start of enrollment: 2012 Jul 01
Terminated
Phase 2
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Start of enrollment: 2013 May 01
Terminated
Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma Start of enrollment: 2013 Aug 01
Suspended
Phase 1, Phase 2
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Start of enrollment: 2021 May 18
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.
Simon Khagi, Rupesh Kotecha, Na Tosha N Gatson, Suriya Jeyapalan, Huda Ismail Abdullah
The Oncologist. 2024-10-14
1 citations
Phase 1 study of concomitant tumor treating fields and temozolomide chemoradiation for newly diagnosed glioblastoma.
Samuel A Goldlust, Samuel Singer, Lori A Cappello, Ahmad K AlMekkawi, Kangmin D Lee
Neuro-Oncology Advances. 2024-07-29
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Samuel A Goldlust, Louis B Nabors, Sigmund Hsu, Nimish Mohile, Paul J Duic
Neuro-Oncology Advances. 2024-01-18

Press Mentions

Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)May 11th, 2022
John Theurer Cancer Center Treats First Patient in U.S. With Investigational New Treatment for Brain CancerMarch 28th, 2022
Hackensack University Medical Center Foundation Celebrates Formal Investiture of Samuel A. Goldlust, M.D.December 4th, 2017
Join now to see all